A Randomized, Open-label, Parallel-Group, Comparative Study in Chinese Healthy Male Subjects to Evaluate the Safety and Pharmacokinetic Profile of TG103 Injection Produced by Two Different Manufacturing Processes
This study is designed to evaluate the comparability of TG103 injection subject to changes in the manufacturing process in Chinese healthy male subjects.
100 Clinical Results associated with CSPC Baike (Yantai) Biopharmaceutical Co. Ltd.
0 Patents (Medical) associated with CSPC Baike (Yantai) Biopharmaceutical Co. Ltd.
100 Deals associated with CSPC Baike (Yantai) Biopharmaceutical Co. Ltd.
100 Translational Medicine associated with CSPC Baike (Yantai) Biopharmaceutical Co. Ltd.